BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that its Alaris™ System infusion platform was cited as having the most customers live with bidirectional electronic medical record (EMR) integration, which health care providers said is the most important next step for improving safety to help reduce pump-programming errors in the Smart Pumps 2016: The Quest for Patient Safety report issued by KLAS.
The report from KLAS (klasresearch.com), an organization that independently monitors health care information technology performance through the active participation of thousands of health care organizations, also stated that BD has the "most comprehensive pump platform." The Alaris System from BD has the most customers live with EMR integration and is reported to be the only infusion platform to achieve EMR integration with syringe pumps.
"This recognition is important because it comes directly from the health care providers who use our products every day," said Mike Garrison, vice president and general manager of worldwide Infusion Solutions for BD. "We continue to invest in innovation to ensure our products are at the forefront of technology to help improve patient safety and care efficiency."
The report also states that a large number of BD customers achieve high drug library compliance, which many credit to BD’s reports and guidance. In addition, the report shows that actionable insights are more highly valued over basic reporting, and BD is leading in this transformation. More customers use BD reports and analytics to drive outcomes than any other infusion pump vendor.
Earlier this year, the Alaris System was named Best in KLAS for Smart Pumps in The 2015 Best in KLAS: Medical Equipment report that stated that providers believe that BD is better positioned for the future in regard to interoperability with electronic medical records (EMRs), and customers appreciate the added benefit of having patient-controlled analgesia (PCA) pumps and syringe pumps on a single platform.
BD (bd.com) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
Contact: Monique N. Dolecki - BD Investor Relations
P: 201-847-5378 - E: monique_dolecki[.]bd.com.